Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Down More Than 23%, This Year's 2 Worst-Performing Dow Stocks Look Like Monster Buys Right Now
02:53pm, Saturday, 23'rd Apr 2022 The Motley Fool
Investors have a rare opportunity to buy Nike and Home Depot on sale.
This Unstoppable Dividend Aristocrat Is 2022's Best-Performing Dow Stock (and It's Not Even Close)
12:56pm, Saturday, 23'rd Apr 2022 The Motley Fool
Chevron stock is a buy despite being up big for the year.
2 Dividend Stocks to Buy and Hold Forever
03:45pm, Friday, 22'nd Apr 2022 The Motley Fool
These two companies have been around a while.
Will X Mark The Spot For Musk As Streaming Wars Heat Up?
02:55pm, Friday, 22'nd Apr 2022 Benzinga
Image credit: WikiMedia Commons
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
(Friday Market Open) Another
Merck (MRK) Earnings Expected to Grow: Should You Buy?
07:01pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 High-Yielding Dividend Stocks You Can Buy and Forget
02:15pm, Thursday, 21'st Apr 2022 The Motley Fool
These are stable businesses that have generous payouts.
Merck (MRK) Gains As Market Dips: What You Should Know
09:45pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
In the latest trading session, Merck (MRK) closed at $86.46, marking a +0.78% move from the previous day.
2 Healthcare Stocks That Could Make You Richer
03:07pm, Wednesday, 20'th Apr 2022 The Motley Fool
These companies should benefit from steadily growing demand for their products and services.
AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag
12:35pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).
Here is how to trade Merck as it hovers at the $90 resistance level
06:12pm, Tuesday, 19'th Apr 2022 Invezz
Merck & Company (NYSE:MRK) closed last week at a valuation of $86.91. This was after opening the week at $88.32 and touching a high of $89.49. Merck faces notable resistance at $90. This resistance is
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
03:50pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
02:55pm, Monday, 18'th Apr 2022 Zacks Investment Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
01:32pm, Monday, 18'th Apr 2022 Zacks Investment Research
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development prog
J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings
01:06pm, Monday, 18'th Apr 2022 Zacks Investment Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.
How well is the COVID-19 test-to-treat program working?
04:49pm, Friday, 15'th Apr 2022 MarketWatch
The Biden administration's test-to-treat program, which allows people who test positive for COVID-19 to leave the pharmacy with a prescription for antivirals, is facing questions about capacity.
